PE20180032A1 - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
PE20180032A1
PE20180032A1 PE2017001543A PE2017001543A PE20180032A1 PE 20180032 A1 PE20180032 A1 PE 20180032A1 PE 2017001543 A PE2017001543 A PE 2017001543A PE 2017001543 A PE2017001543 A PE 2017001543A PE 20180032 A1 PE20180032 A1 PE 20180032A1
Authority
PE
Peru
Prior art keywords
methyl
benzodiazol
hydroxybutanoate
dihydropyridin
tert
Prior art date
Application number
PE2017001543A
Other languages
English (en)
Inventor
Rino Antonio Bit
John Alexander Brown
Philip G Humphreys
Katherine Louise Jones
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PE20180032A1 publication Critical patent/PE20180032A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

Referida a derivados de bencimidazol de formula (I) y sales de los mismos, en la que R1, R2, R3, R4 son como se han definido en la presente memoria. Son compuestos preferidos: (2S,3R)-2-{[(3R)-1-acetilpiperidin-3-il]metil}-2-(1,5-dimetil-6-oxo-1,6-dihidropiridin-3-il)-1H-1,3-benzodiazol-6-il)metil]amino}-3-hidroxibutanoato de terc-butilo, (2S,3R)-2-({[2-(1,5-dimetil-6-oxo-1,6-dihidropiridin-3-il)-1-(oxan-4-ilmetil)-1H-1,3-benzodiazol-6-il]metil}amino)-3-hidroxibutanoato de terc-butilo, entre otros. Dichos compuestos inhiben la union de la familia BET de proteinas de bromodominio a, por ejemplo, residuos de lisina acetilados y por lo tanto son utiles en el tratamiento de enfermedades autoinmunitarias e inflamatorias, tales como artritis reumatoide; y canceres
PE2017001543A 2015-03-19 2016-03-17 Compuestos quimicos PE20180032A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504689.9A GB201504689D0 (en) 2015-03-19 2015-03-19 Chemical compounds

Publications (1)

Publication Number Publication Date
PE20180032A1 true PE20180032A1 (es) 2018-01-09

Family

ID=53052091

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001543A PE20180032A1 (es) 2015-03-19 2016-03-17 Compuestos quimicos

Country Status (35)

Country Link
US (2) US10442786B2 (es)
EP (2) EP3271349B1 (es)
JP (1) JP6419990B2 (es)
KR (1) KR102072850B1 (es)
CN (1) CN107635989B (es)
AR (1) AR103934A1 (es)
AU (1) AU2016232217B2 (es)
BR (1) BR112017019779B1 (es)
CA (1) CA2979504C (es)
CL (1) CL2017002332A1 (es)
CO (1) CO2017009992A2 (es)
CR (1) CR20170430A (es)
CY (1) CY1121855T1 (es)
DK (1) DK3271349T3 (es)
DO (1) DOP2017000213A (es)
EA (1) EA033594B1 (es)
ES (1) ES2735417T3 (es)
GB (1) GB201504689D0 (es)
HR (1) HRP20191186T1 (es)
HU (1) HUE044414T2 (es)
IL (1) IL254318B (es)
LT (1) LT3271349T (es)
MA (2) MA41778A (es)
ME (1) ME03485B (es)
MX (1) MX2017012023A (es)
PE (1) PE20180032A1 (es)
PH (1) PH12017501620A1 (es)
PL (1) PL3271349T3 (es)
PT (1) PT3271349T (es)
RS (1) RS59056B1 (es)
SG (1) SG11201707356QA (es)
SI (1) SI3271349T1 (es)
TW (1) TW201706257A (es)
UY (1) UY36589A (es)
WO (1) WO2016146738A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN108290856A (zh) 2015-08-11 2018-07-17 尼奥迈德研究所 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
IL257340B2 (en) 2015-08-12 2023-10-01 Neomed Inst Converted benzaimidazoles, methods for their preparation and use as pharmaceuticals
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614940D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate
EP3612522A4 (en) 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
CN109280046B (zh) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 苯并咪唑类衍生物及其制备方法及其在医药上的用途
EP3750885A4 (en) * 2018-02-06 2021-10-27 Shanghai Haihe Pharmaceutical Co., Ltd. COMPOUND PRESENTING AN INHIBITORING ACTIVITY OF BET, ITS PREPARATION PROCESS AND ITS USE
CN109369432B (zh) * 2018-11-02 2021-06-25 永农生物科学有限公司 (s)-4-氯-2-氨基丁酸酯的制备方法
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
WO2020190780A1 (en) * 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
AU2020264106A1 (en) * 2019-04-24 2021-12-23 Convergene, Llc Small molecule bromodomain inhibitors and uses thereof
US20220227709A1 (en) * 2019-04-29 2022-07-21 The Board Of Regents Of The University Of Texas System Compositions and methods for treating schistosoma infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
KR101054325B1 (ko) 2006-03-31 2011-08-04 얀센 파마슈티카 엔.브이. 히스타민 h4 수용체 조절제로서의 벤조이미다졸―2―일 피리미딘 및 피라진
EP2493310A4 (en) * 2009-10-27 2014-03-12 Glaxosmithkline Llc BENZIMIDAZOLES AS INHIBITORS OF ACID GRAS SYNTHASE
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CA2895905A1 (en) * 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
KR102244719B1 (ko) 2013-03-15 2021-04-26 플렉시콘 인코퍼레이티드 헤테로시클릭 화합물 및 그의 용도
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US9662311B2 (en) * 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US9428515B2 (en) * 2014-05-09 2016-08-30 Boehringer Ingelheim International Gmbh Benzimidazole derivatives
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201504694D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate

Also Published As

Publication number Publication date
EP3549939A1 (en) 2019-10-09
CN107635989B (zh) 2020-12-08
MX2017012023A (es) 2018-01-30
UY36589A (es) 2016-10-31
HRP20191186T1 (hr) 2019-10-04
IL254318A0 (en) 2017-11-30
US20180044317A1 (en) 2018-02-15
EP3271349A1 (en) 2018-01-24
CO2017009992A2 (es) 2018-01-05
DOP2017000213A (es) 2017-10-15
AR103934A1 (es) 2017-06-14
PL3271349T3 (pl) 2019-10-31
AU2016232217A1 (en) 2017-10-12
WO2016146738A1 (en) 2016-09-22
JP2018507903A (ja) 2018-03-22
MA46981A (fr) 2019-10-09
AU2016232217B2 (en) 2019-04-04
EP3271349B1 (en) 2019-05-15
PH12017501620A1 (en) 2018-02-12
SG11201707356QA (en) 2017-10-30
CA2979504A1 (en) 2016-09-22
PT3271349T (pt) 2019-08-19
SI3271349T1 (sl) 2019-08-30
RS59056B1 (sr) 2019-08-30
MA41778A (fr) 2018-01-24
US10442786B2 (en) 2019-10-15
CN107635989A (zh) 2018-01-26
ES2735417T3 (es) 2019-12-18
US20200039953A1 (en) 2020-02-06
JP6419990B2 (ja) 2018-11-07
GB201504689D0 (en) 2015-05-06
CA2979504C (en) 2023-10-10
BR112017019779A2 (pt) 2018-05-22
DK3271349T3 (da) 2019-08-05
BR112017019779B1 (pt) 2023-10-03
US11053212B2 (en) 2021-07-06
TW201706257A (zh) 2017-02-16
KR20170129871A (ko) 2017-11-27
EA201791973A1 (ru) 2018-07-31
CL2017002332A1 (es) 2018-03-16
CR20170430A (es) 2017-11-08
ME03485B (me) 2020-01-20
IL254318B (en) 2019-08-29
LT3271349T (lt) 2019-07-10
EA033594B1 (ru) 2019-11-07
CY1121855T1 (el) 2020-07-31
HUE044414T2 (hu) 2019-10-28
KR102072850B1 (ko) 2020-02-03

Similar Documents

Publication Publication Date Title
PE20180032A1 (es) Compuestos quimicos
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
CL2014002541A1 (es) Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades.
BR112015029979A2 (pt) composto n-(1,2,4-triazol-3-il)arilcarboxamidas, composição, utilização de um composto e método para o controle da vegetação
CU20160063A7 (es) Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
UA113777C2 (xx) Гербіцидно й фунгіцидно діючі 5-оксизаміщені 3-фенілізоксазолін-5-карбоксаміди і 5-оксизаміщені 3-фенілізоксазолін-5-тіоаміди
CL2016000241A1 (es) Formulación de inhibidores de la syk.
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
UA110241C2 (en) Herbicides and fungicides active phneylisoxazoline 3-5-carboxamide and 3- phneylisoxazoline -5-thioamides
PE20141228A1 (es) Derivados de pirrolopirimidina y purina
BR112013004624A2 (pt) "derivados de furopiridina"
EA201401189A1 (ru) Замещенные n-(тетразол-5-ил)- и n-(триазол-5-ил)арилкарбоксамидные соединения и их применение в качестве гербицидов
BR112015010649A2 (pt) moduladores de gpr40 à base de pirrolidina
UA110372C2 (en) Amide n- (1,2,5-oxadiazoles-3-yl) -, n- (tetrazol-5-yl) - and n- (triazole-5-yl) bitsykloarylkarbonovoyi acid and their use as herbicides
PE20150224A1 (es) Inhibidores del nampt
PH12016500885A1 (en) Novel heterocyclic compounds
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
CO2019001871A2 (es) Derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias o cánceres.
CY1119687T1 (el) Κρυσταλλικο αλας της (s)-(2-(6-χλωρο-7- μεθυλ-1η- βενζο [d]imiδazoλ-2- υλ)-2- μεθυλπυρρολιδιν-1- υλ)(5-μεθοξυ-2-(2η-1,2,3- τριαζολ-2- υλ)φαινυλ) μεθανονης ως ανταγωνιστης υποδοχεα ορεξινης
CO2018004473A2 (es) Compuestos agonistas de ppar y composiciones farmaceuticas